CPhI Japan – organised by UBM EMEA and UBM Asia – returned to Tokyo for its 16th edition (April 19-21st, 2017) with the release of new research into the Japanese pharmaceutical market. Over 90 domestic and international companies attending the event were surveyed to provide a holistic picture of the country’s best growth opportunities. Overall, domestic companies in Japan are forecasting a staggering 17
A sector-by-sector analysis showed that 56
Rutger Oudejans, Brand Director at CPhI for Asia and North America said: “The ever rising demand for anticancer drugs and high margins combined with Japan’s robust reimbursement system for patented drugs make it an attractive market for companies to invest in and develop new drugs.”
Japan has the world’s third largest pharma industry and traditionally its domestic market has thrived. Consequently, only 18
The Japanese Government has committed to increase the market penetration of generics and 28
Nearly 80
“Over the past few days CPhI Japan has provided an unprecedented opportunity for international companies to cultivate innovation and promote investment into Japan’s ever-growing domestic market. The extremely robust patented market combined with the huge growth anticipated for generics, biologics and APIs all provide an appealing platform for big business investments. This will enable Japan to maintain their position as a world leader in the pharmaceutical industry”, commented Rutger Oudejans.
The complete report and analysis will be available later on in the year on the CPhI Pharma Insights website.
